logo
ResearchBunny Logo
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Medicine and Health

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

P. Mlcochova, S. A. Kemp, et al.

The B.1.617.2 (Delta) variant of SARS-CoV-2 poses a significant challenge as it exhibits reduced sensitivity to neutralizing antibodies and increased replication efficiency. Conducted by a diverse team of authors, including Petra Mlcochova and Steven A. Kemp, this research highlights the urgent need for continued infection control measures to combat the Delta variant's immune evasion strategies.

00:00
00:00
Playback language: English
Abstract
The B.1.617.2 (Delta) variant of SARS-CoV-2 showed reduced sensitivity to neutralizing antibodies from recovered individuals and monoclonal antibodies. It demonstrated higher replication efficiency than B.1.1.7 and higher receptor binding and spike-mediated entry than B.1.617.1. Analysis of healthcare workers showed reduced ChAdOx vaccine effectiveness against B.1.617.2. The study concludes that the Delta variant's high fitness and immune evasion warrant continued infection control measures.
Publisher
Nature
Published On
Jul 28, 2021
Authors
Petra Mlcochova, Steven A. Kemp, Mahesh Shankar Dhar, Guido Papa, Bo Meng, Isabella A. T. M. Ferreira, Rawlings Dati, Dana M. Collier, Anna Albeck, Sujeet Singh, Rajesh Pandey, Jonathan Brown, Jie Zhou, Niiuka Goonawardena, Swapnil Mishra, Charles Whittaker, Thomas Mellan, Robin Marwal, Meena Datt, Shantanu Sengupta, Kalaiarasuan Ponnuswamy, Venkataraman Srinivasan Radhakrishnan, Adam Abdullah, Oscar Charles, Partha Chattopadhyay, Priti Devi, Daniela Caputo, Tom Peacock, Chand Watstal, Neeraj Goel, Ambrish Satwik, Raj Vaishya, Meenakshi Agarwal, The Indian SARS-CoV-2 Genomics Consortium (INSACOG), The Complete to Phenotype Japan (G2P-Japan) Consortium, The CTIID-NIHR BioResource COVID-19 Collaboration, Antriksh Mavcousiãn, Joo Hyoen Lee, Jessica Bassi, Chiara Silacci-Fregni, Christian Saliba, Dora Pinto, Takashi Irie, Isao Yoshida, William L. Hamilton, Kei Sato, Samir Bhatt, Seth Flaxman, Leo C. James, Davide C. Lucco, Wendy S. Barclay, Partha Rakshit, Anurag Agarwal, Ravindra K. Gupta
Tags
SARS-CoV-2
Delta variant
neutralizing antibodies
vaccine effectiveness
infection control
immune evasion
replication efficiency

Related Publications

Explore these studies to deepen your understanding of the subject.

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
Medicine and Health

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

M. Gagne, B. J. Flynn, et al.

SARS-CoV-2 variant biology: immune escape, transmission and fitness
Biology

SARS-CoV-2 variant biology: immune escape, transmission and fitness

A. M. Carabelli, T. P. Peacock, et al.

Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia
Biology

Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia

J. Y. L. Fu, M. H. Pukhari, et al.

Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants
Medicine and Health

Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants

C. Sun, Y. Kang, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny